{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:29:12Z","timestamp":1790512152591,"version":"4.1.0"},"reference-count":130,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Disease relapse represents by far the most frequent cause of hematopoietic cell transplantation (HCT) failure. Patients with acute leukemia suffering relapse after HCT have limited conventional treatment options with little possibility of cure and represent, de facto, suitable candidates for the evaluation of novel cellular and biological-based therapies. Donor lymphocyte infusions (DLI) has been one of the first cellular therapies adopted to treat post HCT relapse of acute leukemia patients and still now, it is widely adopted in preemptive and prophylactic settings, with renewed interest for manipulated cellular products such as NK-DLI. The acquisition of novel biological insights into pathobiology of leukemia relapse are translating into the clinic, with novel combinations of target therapies and novel agents, helping delineate new therapeutical landscapes. Hypomethylating agents alone or in combination with novel drugs demonstrated their efficacy in pre-clinical models and controlled trials. FLT3 inhibitors represent an essential therapeutical instrument incorporated in post-transplant maintenance strategies. The Holy grail of allogeneic transplantation lies in the separation of graft-vs.-host disease from graft vs. tumor effects and after more than five decades, is still the most ambitious goal to reach and many ways to accomplish are on their way.<\/jats:p>","DOI":"10.3389\/fonc.2022.1066285","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T07:16:37Z","timestamp":1669792597000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia"],"prefix":"10.3389","volume":"12","author":[{"given":"Enrico","family":"Maffini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Ursi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Dicataldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Roberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Campanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Felice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"De Matteis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Storci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Bonaf\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Arpinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bonifazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0171-z","article-title":"Epidemiology and biology of relapse after stem cell transplantation","volume":"53","author":"Horowitz","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13315","article-title":"Survival of early post hematopoietic stem cell transplantation relapse of myeloid malignancies","volume":"103","author":"De Jong","year":"2019","journal-title":"Eur J Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: A center for international blood and marrow transplant research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.06.007","article-title":"Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation","volume":"13","author":"Mielcarek","year":"2007","journal-title":"Bio Blood Marrow Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01163-z","article-title":"Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and clinical outcomes","volume":"56","author":"Yanada","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","first-page":"771.e1","DOI":"10.1016\/j.jtct.2021.05.011","article-title":"Relapse after allogeneic stem cell transplantation of acute myelogenous leukemia and myelodysplastic syndrome and the importance of second cellular therapy","volume":"27","author":"Brambilla Zuanelli","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.139105","article-title":"Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia","volume":"101","author":"Ossenkoppele","year":"2016","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.09.011","article-title":"Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation","volume":"19","author":"Thanarajasingam","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03670-6","article-title":"Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies","volume":"98","author":"Schuler","year":"2019","journal-title":"Ann Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-846824","article-title":"Mechanisms of immune escape after allogeneic hematopoietic cell transplantation","volume":"133","author":"Zeiser","year":"2019","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N Eng J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/leu.2014.314","article-title":"Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation","volume":"29","author":"Crucitti","year":"2015","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01081-0","article-title":"HLA-haplotype loss after TCR \u03b1\u03b2\/CD19-depleted haploidentical HSCT","volume":"56","author":"Shyr","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B14","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1182\/blood-2018-99-112142","article-title":"Incidence of HLA loss in a global multicentric cohort of post-transplantation relapses: Results from the hlaloss collaborative study","volume":"132","author":"Vago","year":"2018","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03273-w","article-title":"Downregualtion of HLA class II is associated with relapse after allogeneic stem cell transplantation and alters recognition by antigen-specific T cells","volume":"115","author":"Adachi","year":"2022","journal-title":"Int J Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Cristopher","year":"2018","journal-title":"N Eng J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000445","article-title":"Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation","volume":"3","author":"Jan","year":"2019","journal-title":"Blood Adv"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0980","article-title":"Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse","volume":"12","author":"Gambacorta","year":"2022","journal-title":"Cancer Discovery"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.11.027","article-title":"Increased coexpression of PD-1, TIGIT, and KLRG-1 on tumor-reactive CD8+ T cells during relapse after allogeneic stem cell transplantation","volume":"24","author":"Hutten","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.158.5.2065","article-title":"TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression","volume":"158","author":"Lee","year":"1997","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"98962","DOI":"10.1172\/jci.insight.98962","article-title":"Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant","volume":"3","author":"Jacoby","year":"2018","journal-title":"JCI Insight"},{"key":"B25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1182\/bloodadvances.2016000760","article-title":"Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia","volume":"1","author":"Quek","year":"2016","journal-title":"Blood Adv"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0342","article-title":"Graft-versus-leukemia reactions in allogeneic chimeras","volume":"103","author":"Kolb","year":"2004","journal-title":"Blood."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.03.030","article-title":"Reversal of T cell exhaustion by the first donor lymphocyte infusion is associated with the persistently effective antileukemic responses in patients with relapsed AML after allo-HSCT","volume":"24","author":"Liu","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109992","article-title":"Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy","volume":"37","author":"Bachireddy","year":"2021","journal-title":"Cell Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.58","article-title":"PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation","volume":"5","author":"Kong","year":"2015","journal-title":"Blood Cancer J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86175","article-title":"Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response","volume":"127","author":"Van Bergen","year":"2017","journal-title":"J Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004073","article-title":"Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI","volume":"5","author":"Schultze-Florey","year":"2021","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0536-y","article-title":"Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"54","author":"Guillame","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-072470","article-title":"Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia","volume":"109","author":"Dominietto","year":"2007","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/ejh.12591","article-title":"Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs-Host disease control for minimal residual disease in acute Leukemia\/Myelodisplastic syndrome after allogeneic hematopoietic stem cell tran","volume":"96","author":"Mo","year":"2016","journal-title":"Eur J Haematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.234","article-title":"Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation","volume":"51","author":"Jedlickova","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.150326","article-title":"Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia","volume":"102","author":"Mohty","year":"2017","journal-title":"Haematologica"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24949","article-title":"Donor lymphocyte infusion and methotrexate for immune recovery after T-cell depleted haploidentical transplantation","volume":"93","author":"Gilman","year":"2018","journal-title":"Am J Haematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15544","article-title":"Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: A retrospective bicentric analysis of serial infusions of increasing doses of CD3+ cells","volume":"185","author":"Cauchois","year":"2019","journal-title":"Br J Haematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01088-7","article-title":"Prophylactic modified donor lymphocyte infusion after low-dose ATG-f-based haploidentical HSCT with myeloablative conditioning in high-risk acute leukemia: a matched pair analysis","volume":"56","author":"Yang","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B45","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41408-021-00519-y","article-title":"Mixed T cell lineage chimerism in acute leukemia\/MDS using pre-emptive donor lymphocyte infusion strategy-is it prognostic?- a single-center retrospective study","volume":"11","author":"Sheth","year":"2021","journal-title":"Blood Cancer J"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3763","article-title":"Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with\/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study","volume":"10","author":"Zhang","year":"2021","journal-title":"Cancer Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.242","article-title":"Phase I\/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)","volume":"31","author":"Bug","year":"2017","journal-title":"Leukemia."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002074","article-title":"Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation","volume":"4","author":"Kalin","year":"2020","journal-title":"Blood Adv"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04494-z","article-title":"Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: A single-center landmark analysis","volume":"100","author":"Rettig","year":"2021","journal-title":"Ann Hematol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.12.013","article-title":"Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes","volume":"19","author":"Kryshnamurthy","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1182\/blood-2021-152578","article-title":"Comparison of prophylactic and preemptive donor lymphocyte infusion in patients with very high risk acute leukemia after allogeneic hematopoietic stem cell transplantation","volume":"138","author":"Yang","year":"2021","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6053","article-title":"Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3324\/haematol.2019.219790","article-title":"Clinical applications of donor lymphocyte infusion from a HLA-haploidentical donor: consensus recommendation from the acute leukemia working party of the EBMT","volume":"105","author":"Dholaria","year":"2020","journal-title":"Haematologica"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01515-3","article-title":"Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia","volume":"57","author":"Schmid","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.2","article-title":"Premptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favourable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: A prospective","volume":"49","author":"Solomon","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25211","article-title":"Measurable residual disease, conditioning regimen intensity, and age predict outcomes of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the acute leukemia working party","volume":"93","author":"Gilleece","year":"2018","journal-title":"Am J Hematol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.167","article-title":"Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. a review from the ALWP of the EBMT","volume":"51","author":"Tsirigotis","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12524","article-title":"Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"54","author":"Tan","year":"2014","journal-title":"Transfusion"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e19014","article-title":"Outcomes with preemptive donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes: A systematic review and meta-analysis","volume":"39","author":"Hussain","year":"2021","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2017.07.004","article-title":"T Cell costimulation blockade promotes transplantation tolerance in combination with sirolimus and post-transplantation cyclophosphamide for haploidentical transplantation in children with severe aplastic anemia","author":"Jaiswal","year":"2017","journal-title":"Transpl Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01839-8","article-title":"Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party","author":"Santoro","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B62","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/jcm9010039","article-title":"Immnulogical and clinical impact of manipulated and unmanipulated DLI after allogeneic stem cell transplantation of AML patients","volume":"9","author":"Greiner","year":"2020","journal-title":"J Clin Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347070","article-title":"NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions","volume":"118","author":"Foley","year":"2011","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13287-022-02769-4","article-title":"Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer","volume":"13","author":"Kennedy","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B65","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: you can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.3390\/cancers13112673","article-title":"Phase I trial of propphylactic donor-derived il-2-Activated nk cell infusion after allogeneic hematopoietic stem cell transplantation from a matched sibling donor","volume":"13","author":"Devillier","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e154334","DOI":"10.1172\/JCI154334","article-title":"Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse","volume":"132","author":"Shapiro","year":"2022","journal-title":"J Clin Invest"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01349-4","article-title":"Decrease post-transplant relapse using donor-derived expanded NK-cells","volume":"36","author":"Ciurea","year":"2022","journal-title":"Leukemia"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01002-1","article-title":"CTLA4Ig-primed donor lymphocyte infusions following haploidentical transplantation improve outcome with a distinct pattern of early immune reconstitution as compared to conventional donor lymphocyte infusions in advanced hematological malignancies","volume":"56","author":"Jaiswal","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3109\/14653249.2011.586997","article-title":"Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex-haplo-identical non-myeloablative hematopoietic cell transplantation","volume":"13","author":"Chen","year":"2011","journal-title":"Cytotherapy."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0733-0","article-title":"ATIR101 administered after T-cell-Depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia","volume":"34","author":"Roy","year":"2020","journal-title":"Leukemia"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0991-5","article-title":"Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation","volume":"56","author":"Maung","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23825","article-title":"Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation","volume":"89","author":"Ho","year":"2014","journal-title":"Am J Hematol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1084\/jem.174.1.139","article-title":"Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity","volume":"174","author":"Schmidt-Wolf","year":"1991","journal-title":"J Exp Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s002620000111","article-title":"Resistance of ex vivo expanded CD3+CD56+ T cells to fas-mediated apoptosis","volume":"49","author":"Verneris","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.03.004","article-title":"Clearance of hematologic malignancies by allogeneic cytokine-induced killer cell or donor lymphocyte infusions","volume":"25","author":"Merker","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.07.005","article-title":"Phase II study of sequential infusion of donor lymphocyte infusion and cytokine-induced killer cells for patients relapsed after allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Introna","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.05.021","article-title":"Targeting CD33 in chemoresistant AML patient-derived xenografts by CAR-CIK cells modified with an improved SB transposon system","volume":"28","author":"Rotiroti","year":"2020","journal-title":"Mol Ther"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/22.10.1615","article-title":"DNA Hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas","volume":"22","author":"Nie","year":"2001","journal-title":"Carcinogenesis"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22141","article-title":"Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia","volume":"86","author":"Atanackovic","year":"2011","journal-title":"Am J Hematol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3324","article-title":"Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS\/AML patients: A rationale for combined targeting of PD-1 and DNA methylation","volume":"6","author":"Orskov","year":"2015","journal-title":"Oncotarget"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.8.4253","article-title":"Crucial role of DNA methylation in determination of clonally distributed killer cell ig-like receptor expression patterns in NK cells","volume":"169","author":"Santourlidis","year":"2002","journal-title":"J Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-257253","article-title":"In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia","volume":"116","author":"Choi","year":"2010","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24198","article-title":"Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia","volume":"115","author":"Jabbour","year":"2009","journal-title":"Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25500","article-title":"Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndromes","volume":"116","author":"de Lima","year":"2010","journal-title":"Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.05.026","article-title":"Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome","volume":"21","author":"Pusic","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.004","article-title":"Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial","volume":"22","author":"Craddock","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.06.007","article-title":"A phase II multicenter study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplant for high-risk myelodysplasia (and older patients with acute myeloid leukemia): Results of CALGB 100801 (Alliance)","volume":"25","author":"Vij","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B92","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs","volume":"4","author":"Oran","year":"2020","journal-title":"observation after Transplant high-risk AML MDS patients Blood Adv"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03277","article-title":"Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: An open-label, multicenter, randomized controlled trial","volume":"38","author":"Gao","year":"2020","journal-title":"J Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.265","article-title":"Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes","volume":"30","author":"Garcia-Manero","year":"2016","journal-title":"Leukemia."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.06.016","article-title":"CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes","volume":"24","author":"de Lima","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B96","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2020-134272","article-title":"Maintenance treatment with guadecitabine (SGI-110) in high risk MDS and AML patients after allogeneic stem cell transplantation","volume":"136","author":"Oran","year":"2020","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04674-x","article-title":"Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation","volume":"101","author":"Zhao","year":"2022","journal-title":"Ann Hematol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04398-y","article-title":"Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. a retrospective multicenter trial","volume":"100","author":"Amit","year":"2021","journal-title":"Ann Hematol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04321-x","article-title":"Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German cooperative transplant study group","volume":"100","author":"Schuler","year":"2021","journal-title":"Ann Hematol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.067629","article-title":"Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENMAINT trial","volume":"97","author":"Sockel","year":"2012","journal-title":"Haematologica"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood.V130.Suppl_1.1703.1703","article-title":"Effect of azacitidine on CD4+C25+Foxp3+ regulatory T cell on immunity in myelodysplastic syndrome survivors","volume":"130","author":"Tajima","year":"2017","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00889","article-title":"Combination lenalidomide and azacitidine: A novel salvage therapy in patients who relapse after allogeneic stem-cell transplantation for acute myeloid leukemia","volume":"37","author":"Craddock","year":"2019","journal-title":"J Clin Oncol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1182\/blood-2021-153282","article-title":"Treatment of MDS, AML and CMML relapse after allogeneic blood stem cell transplantation with azacitidine, lenalidomide and donor lymphocyte infusions - final results of the prospective azalena-trial (NCT02472691)","volume":"138","author":"Schroeder","year":"2021","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.09.016","article-title":"Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation","volume":"86","author":"Metzelder","year":"2017","journal-title":"Eur J Cancer"},{"key":"B107","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.14260","article-title":"Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission","volume":"175","author":"Brunner","year":"2016","journal-title":"Br J Haematol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2461-5","article-title":"Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation","volume":"94","author":"Tschan-Plessl","year":"2015","journal-title":"Ann Hematol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-693648","article-title":"How I treat FLT3-mutated AML","volume":"129","author":"Pratz","year":"2017","journal-title":"Blood."},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243410","article-title":"Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the acute leukemia working party of the European society for blood and marrow transplantation","volume":"105","author":"Bazarbachi","year":"2020","journal-title":"Haematologica."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12832","article-title":"Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT","volume":"98","author":"Rautenberg","year":"2017","journal-title":"Eur J Hematol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-869453","article-title":"German-Austrian AML study group. midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD","volume":"133","author":"Schlenk","year":"2019","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01153-1","article-title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","volume":"56","author":"Maziarz","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000174","article-title":"Gilteritinib: potent targeting of FLT3 mutations in AML","volume":"4","author":"Levis","year":"2020","journal-title":"Blood Adv"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.162.10.5813","article-title":"CTLA-4-Mediated inhibition of early events of T cell proliferation","volume":"162","author":"Brunner","year":"1999","journal-title":"J Immunol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.2.1052","article-title":"CTLA-4 overexpression inhibits T cell responses through a CD28-B7-Dependent mechanism","volume":"177","author":"Engelhardt","year":"2006","journal-title":"J Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundatios of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat Rev Drug Discovery"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-004-0978-0","article-title":"High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML)","volume":"84","author":"Graf","year":"2005","journal-title":"Ann Hematol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136235","article-title":"Safety and efficacy of decitabine plus ipilimumab in relapsed or refractory MDS\/AML in the post-BMT or transplant na\u00efve settings","volume":"136","author":"Garcia","year":"2020","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0523","article-title":"The role of IDH mutations in acute myeloid leukemia","volume":"14","author":"Montalban-Bravo","year":"2018","journal-title":"Future Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.04.007","article-title":"Allogeneic hematopoietic cell transplantation outcomes in patients carrying isocitrate dehydrogenase mutations","volume":"19","author":"Salhotra","year":"2019","journal-title":"Clin Lymphoma Myel Leuk"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016082","article-title":"Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1\/2 upregulation","volume":"140","author":"Ho","year":"2022","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1182\/blood-2021-151455","article-title":"Allogeneic hematopoietic cell transplantation outcomes of patients with R\/R AML of higher-risk MDS treated with the TIM-3 inhibitor MBG453 (Sabatolimab) and hypomethylating agents","volume":"138","author":"Brunner","year":"2021","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1066285\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T07:16:43Z","timestamp":1669792603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1066285\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":130,"alternative-id":["10.3389\/fonc.2022.1066285"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1066285","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"article-number":"1066285"}}